Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011).

The guidelines for secondary prevention of myocardial infarction (MI) in Japan were developed by the Joint Working Groups consisting of representatives of various academic societies in the field of cardiovascular diseases including the Japanese Circulation Society (JCS) and the Japanese College of Cardiology. The first edition of the guidelines were published in 20001 under the title of “Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (1998–1999 Joint Working Groups Report): Guidelines for Secondary Prevention of Myocardial Infarction (Chair: Masahiko Kinoshita)”. Later, the first update, “Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2004–2005 Joint Working Groups Report): Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2006) (Chair: Kinji Ishikawa)”, was prepared.2 The present version is the second update. We prepared this 2011 update to include evidences obtained in Japan as much as possible and to fit the current situation in Japan, where coronary intervention is a common procedure. We hope that these guidelines will be used widely in the clinical setting in Japan to improve the prognosis of patients with M

[1]  M. Shoda,et al.  Guidelines for Non-Pharmacotherapy of Cardiac Arrhythmias (JCS 2011). , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[2]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[3]  K. Swedberg,et al.  Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. , 2010, European heart journal.

[4]  D. Grobbee,et al.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.

[5]  S. Connolly,et al.  Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. , 2010, Journal of the American College of Cardiology.

[6]  J. Gore,et al.  Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patients in the Global Registry of Acute Coronary Events. , 2010, European heart journal.

[7]  H. Yagi,et al.  Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[8]  C. White,et al.  Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin IIReceptor Blockers for Ischemic Heart Disease , 2009, Annals of Internal Medicine.

[9]  J. Connell,et al.  Aldosterone status associated with insulin resistance in patients with heart failure—data from the ALOFT study , 2009, Heart.

[10]  Hakuo Takahashi,et al.  Oral nicorandil to reduce cardiac death after coronary revascularization in hemodialysis patients: a randomized trial. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  Katsumi Miyauchi,et al.  Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin , 2009, Journal of the American College of Cardiology.

[12]  N. Schneiderman,et al.  The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. , 2009, Journal of psychosomatic research.

[13]  J. McMurray,et al.  Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? , 2009, American heart journal.

[14]  P. Sever,et al.  Managing cardiovascular and renal risk: the potential of direct renin inhibition , 2009, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[15]  Hae-Young Lee,et al.  Cardio–renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program , 2009, Expert review of cardiovascular therapy.

[16]  M. Hirai,et al.  Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[17]  G. Bakris,et al.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.

[18]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[19]  S. Kusachi,et al.  Serum N-3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[20]  D. Horstkotte,et al.  Adaptive servoventilation improves cardiac function in patients with chronic heart failure and Cheyne–Stokes respiration , 2008, European journal of heart failure.

[21]  S. Yano,et al.  Comparison of sarpogrelate and ticlopidine in bare metal coronary stent implantation. , 2008, International journal of cardiology.

[22]  S. Solomon,et al.  Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure , 2008, Circulation. Heart failure.

[23]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[24]  D. Yuh,et al.  Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data. , 2008, The Journal of thoracic and cardiovascular surgery.

[25]  N. Hagiwara,et al.  Long-Term Nitrate Use in Acute Myocardial Infarction (The Heart Institute of Japan, Department of Cardiology Nitrate Evaluation Program) , 2008, Cardiovascular Drugs and Therapy.

[26]  O. Pedersen,et al.  Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.

[27]  R. Nagai,et al.  Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[28]  A. Hirayama,et al.  Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials , 2007, The Lancet.

[29]  Deepak L. Bhatt,et al.  Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.

[30]  A. Skene,et al.  The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. , 2007, Journal of the American College of Cardiology.

[31]  M. Pfeffer,et al.  Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system , 2007, Journal of hypertension.

[32]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[33]  C. Tei,et al.  Long-term nitrate therapy after acute myocardial infarction does not improve or aggravate prognosis. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[34]  L. Køber,et al.  A systematic review: Effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction , 2007, European journal of heart failure.

[35]  T. Kurata,et al.  Prognostic value of the metabolic syndrome for long-term outcomes in patients undergoing percutaneous coronary intervention. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[36]  Dan M. Roden,et al.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines , 2006 .

[37]  S. Yusuf,et al.  Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials , 2006, The Lancet.

[38]  Nick Freemantle,et al.  Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. , 2006, European heart journal.

[39]  G. Mancia,et al.  Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology. , 2006, European heart journal.

[40]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.

[41]  W. Weaver,et al.  Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. , 2006, Journal of the American College of Cardiology.

[42]  H. Shimomura,et al.  Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. , 2006, The American journal of cardiology.

[43]  P. Steg,et al.  Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. , 2006, Archives of internal medicine.

[44]  F. Dagenais,et al.  Influence of time elapsed between myocardial infarction and coronary artery bypass grafting surgery on operative mortality. , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[45]  C. O'connor,et al.  Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. , 2005, Journal of the American College of Cardiology.

[46]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[47]  A. Moss,et al.  Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). , 2005, The American journal of cardiology.

[48]  M. Nobuyoshi,et al.  Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[49]  X. Drouot,et al.  Compliance with and effectiveness of adaptive servoventilation versus continuous positive airway pressure in the treatment of Cheyne-Stokes respiration in heart failure over a six month period , 2005, Heart.

[50]  D. Tanné,et al.  Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. , 2005, Archives of internal medicine.

[51]  S. Hosoda,et al.  Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[52]  C. Rochitte,et al.  Late coronary artery recanalization effects on left ventricular remodelling and contractility by magnetic resonance imaging. , 2005, European heart journal.

[53]  H. Dargie Heart failure post-myocardial infarction: a review of the issues , 2005, Heart.

[54]  M. Chiariello,et al.  Late reopening of an occluded infarct related artery improves left ventricular function and long term clinical outcome , 2005, Heart.

[55]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[56]  M. Briel,et al.  Effect of different antilipidemic agents and diets on mortality: a systematic review. , 2005, Archives of internal medicine.

[57]  J. McMurray,et al.  Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. , 2005, Journal of the American College of Cardiology.

[58]  Y. Kagaya,et al.  Poor prognosis of Japanese patients with chronic heart failure following myocardial infarction--comparison with nonischemic cardiomyopathy. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[59]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[60]  I. Olkin,et al.  Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials. , 2004, American heart journal.

[61]  A. Skene,et al.  Impact of nicorandil in angina: subgroup analyses , 2004, Heart.

[62]  G. Braunstein,et al.  Meta-Analysis: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction , 2004, Annals of Internal Medicine.

[63]  J. Schroeder,et al.  Effects of Cardiac Resynchronization on Disease Progression in Patients With Left Ventricular Systolic Dysfunction, an Indication for an Implantable Cardioverter-Defibrillator, and Mildly Symptomatic Chronic Heart Failure , 2004, Circulation.

[64]  J. Reiber,et al.  Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study. , 2004, International journal of cardiology.

[65]  F. Fernández‐Avilés,et al.  Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial , 2004, The Lancet.

[66]  K. Shimada,et al.  Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study , 2004, Circulation.

[67]  K. Swedberg,et al.  [Expert Consensus document on beta-adrenergic receptor blockers]. , 2004, Revista espanola de cardiologia.

[68]  H. Ueshima,et al.  [Weight-control intervention in overweight subjects at high risk of cardiovascular disease: a trial of a public health practical training program in a medical school]. , 2004, [Nihon koshu eisei zasshi] Japanese journal of public health.

[69]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[70]  S. Ebrahim,et al.  Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. , 2004, The American journal of medicine.

[71]  E. Gurfinkel,et al.  Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. , 2004, European heart journal.

[72]  T. Takebayashi,et al.  Stages of change for salt intake and urinary salt excretion: baseline results from the High-Risk and Population Strategy for Occupational Health Promotion (HIPOP-OHP) study. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[73]  S. Hosoda,et al.  Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. , 2004, American heart journal.

[74]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[75]  Peter C Austin,et al.  Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.

[76]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[77]  E. Foster,et al.  Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. , 2003, Journal of the American College of Cardiology.

[78]  S. Hosoda,et al.  Effect of trapidil on cardiovascular events in patients with coronary artery disease (results from the Japan Multicenter Investigation for Cardiovascular Diseases-Mochida [JMIC-M]). , 2003, The American journal of cardiology.

[79]  U. Zeymer,et al.  Randomized Comparison of Percutaneous Transluminal Coronary Angioplasty and Medical Therapy in Stable Survivors of Acute Myocardial Infarction With Single Vessel Disease: A Study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte , 2003, Circulation.

[80]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[81]  P. Elliott,et al.  Higher blood pressure in middle-aged American adults with less education—role of multiple dietary factors: The INTERMAP Study , 2003, Journal of Human Hypertension.

[82]  H. Ueshima,et al.  Differences in cardiovascular disease risk factors between Japanese in Japan and Japanese-Americans in Hawaii: the INTERLIPID study , 2003, Journal of Human Hypertension.

[83]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[84]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[85]  N. Frasure-smith,et al.  Depression and other psychological risks following myocardial infarction. , 2003, Archives of general psychiatry.

[86]  R. Canby,et al.  Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. , 2003, JAMA.

[87]  P. Armstrong,et al.  Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. , 2003, Annals of internal medicine.

[88]  Peter Sleight,et al.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. , 2003, JAMA.

[89]  D. Williamson,et al.  Intentional Weight Loss and Death in Overweight and Obese U.S. Adults 35 Years of Age and Older , 2003, Annals of Internal Medicine.

[90]  H. Ogawa,et al.  Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. , 2003, The American journal of cardiology.

[91]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. , 2002, The New England journal of medicine.

[92]  E. Rimm,et al.  Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. , 2003, The New England journal of medicine.

[93]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[94]  H. Arnesen,et al.  Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.

[95]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.

[96]  R. Califf,et al.  Sertraline treatment of major depression in patients with acute MI or unstable angina , 2002, European Neuropsychopharmacology.

[97]  N. Hagiwara,et al.  Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[98]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[99]  V. Fuster,et al.  AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Circulation.

[100]  D. Bush,et al.  Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. , 2001, The American journal of cardiology.

[101]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[102]  J. Gore,et al.  Outcomes and early revascularization for patients > or = 65 years of age with cardiogenic shock. , 2001, The American journal of cardiology.

[103]  M. Biase,et al.  Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. , 2001, Journal of the American College of Cardiology.

[104]  M. Oz,et al.  Optimal timing of revascularization: transmural versus nontransmural acute myocardial infarction. , 2001, The Annals of thoracic surgery.

[105]  J. Daubert,et al.  Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. , 2001, The New England journal of medicine.

[106]  M. Goolsby,et al.  Treating Tobacco Use and Dependence , 2008, Pediatrics.

[107]  S. Connolly,et al.  Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. , 2000, European heart journal.

[108]  H. Ueshima,et al.  Effectiveness of smoking-cessation intervention in all of the smokers at a worksite in Japan. , 2000, Industrial health.

[109]  A. Jacobs,et al.  Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction : A report from the shock trial Registry , 2000 .

[110]  R. Cappato,et al.  Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). , 2000, Circulation.

[111]  Bezafibrate Infarction Prevention study Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[112]  J. Hedner,et al.  Respiratory disturbance index: an independent predictor of mortality in coronary artery disease. , 2000, American journal of respiratory and critical care medicine.

[113]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[114]  M Gent,et al.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. , 2000, Circulation.

[115]  I. Piña,et al.  AHA Science Advisory. Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association; Position paper endo , 2000, Circulation.

[116]  Berndt Lüderitz,et al.  Obstructive Sleep Apnea as a Risk Marker in Coronary Artery Disease , 2000, Cardiology.

[117]  E. Prystowsky,et al.  Implantable defibrillator event rates in patients with unexplained syncope and inducible sustained ventricular tachyarrhythmias: a comparison with patients known to have sustained ventricular tachycardia. , 1999, Journal of the American College of Cardiology.

[118]  P. Lavie,et al.  Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease: effects of continuous positive air pressure treatment. , 1999, Journal of the American College of Cardiology.

[119]  S. Markowitz,et al.  Long-term outcome of patients with unexplained syncope treated with an electrophysiologic-guided approach in the implantable cardioverter-defibrillator era. , 1999, Journal of the American College of Cardiology.

[120]  Roberto Marchioli,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .

[121]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[122]  Y. Tamura,et al.  Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. , 1999, The American journal of cardiology.

[123]  J. Gurwitz,et al.  Temporal trends in cardiogenic shock complicating acute myocardial infarction. , 1999, The New England journal of medicine.

[124]  L. Bujanda,et al.  Mortality and light to moderate alcohol consumption after myocardial infarction , 1999, The Lancet.

[125]  M. Pfeffer,et al.  Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. , 1999, Journal of the American College of Cardiology.

[126]  CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[127]  K. Gould,et al.  Intensive lifestyle changes for reversal of coronary heart disease. , 1998, JAMA.

[128]  P C Deedwania,et al.  Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. , 1998, Circulation.

[129]  M. Kinoshita,et al.  Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. , 1998, Circulation.

[130]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[131]  R. Collins,et al.  Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. , 1998, Circulation.

[132]  P. Lavori,et al.  Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. , 1997, Circulation.

[133]  C. Schuger,et al.  Implantable Cardioverter Defibrillator Utilization Among Device Recipients Presenting Exclusively with Syncope or Near‐Syncope , 1997, Journal of cardiovascular electrophysiology.

[134]  H. Arendrup,et al.  Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. , 1997, Circulation.

[135]  G A Colditz,et al.  A prospective study of passive smoking and coronary heart disease. , 1997, Circulation.

[136]  A. Tamura,et al.  Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group. , 1997, The American journal of cardiology.

[137]  S. Connolly,et al.  Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT , 1997, The Lancet.

[138]  A. Camm,et al.  Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT , 1997, The Lancet.

[139]  J. Manson,et al.  Moderate Alcohol Consumption and Risk for Angina Pectoris or Myocardial Infarction in U.S. Male Physicians , 1997, Annals of Internal Medicine.

[140]  P. J. Wang,et al.  High incidence of appropriate implantable cardioverter-defibrillator therapy in patients with syncope of unknown etiology and inducible ventricular arrhythmias. , 1997, Journal of the American College of Cardiology.

[141]  M. Dennis A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[142]  J. Lubsen,et al.  Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. , 1996, Heart.

[143]  K Steenland,et al.  Environmental tobacco smoke and coronary heart disease in the American Cancer Society CPS-II cohort. , 1996, Circulation.

[144]  G. Breithardt,et al.  Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. , 1996, Circulation.

[145]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[146]  M. Block,et al.  Nonpharmacological therapy for malignant ventricular arrhythmias: implantable defibrillator trials. , 1996, Progress in cardiovascular diseases.

[147]  H. Crijns,et al.  Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors. A randomized study. , 1996, Circulation.

[148]  F. Messerli,et al.  Nifedipine and mortality. Grave defects in the dossier. , 1995, Circulation.

[149]  B. Psaty,et al.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.

[150]  T. Raghunathan,et al.  The risk of myocardial infarction associated with antihypertensive drug therapies. , 1995, JAMA.

[151]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[152]  M. Fujishima,et al.  The impact of alcohol and hypertension on stroke incidence in a general Japanese population. The Hisayama Study. , 1995, Stroke.

[153]  M. Hull,et al.  AICD™ Automatic Cardioverier Defibrillator Clinical Update: 14 Years Experience in Over 34,000 Patients , 1995, Pacing and clinical electrophysiology : PACE.

[154]  J. Manson,et al.  Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. , 1994, Archives of internal medicine.

[155]  S. Glasser,et al.  Phenomenon of nitrate tolerance. , 1994, American heart journal.

[156]  A. G. Shaper,et al.  Alcohol and coronary heart disease: a perspective from the British Regional Heart Study. , 1994, International journal of epidemiology.

[157]  C. Dennis,et al.  A Case-Management System for Coronary Risk Factor Modification after Acute Myocardial Infarction , 1994, Annals of Internal Medicine.

[158]  K. Kuck,et al.  Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). , 1994, American heart journal.

[159]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[160]  M. Gheorghiade,et al.  WITHDRAWAL OF DIGOXIN FROM PATIENTS WITH CHRONIC HEART FAILURE TREATED WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS , 2010 .

[161]  N. Frasure-smith,et al.  Depression following myocardial infarction. Impact on 6-month survival. , 1993, JAMA.

[162]  C. Furberg,et al.  Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. , 1993, JAMA.

[163]  B. Uretsky,et al.  Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. , 1993, Journal of the American College of Cardiology.

[164]  J. Mason A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. , 1993, The New England journal of medicine.

[165]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[166]  R. Kronmal,et al.  Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. , 1992, Journal of the American College of Cardiology.

[167]  G. Guiraudon,et al.  Reduction in defibrillator shocks with an implantable device combining antitachycardia pacing and shock therapy. , 1991, Journal of the American College of Cardiology.

[168]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[169]  F. Marchlinski,et al.  Value of ventricular electrogram recordings in the diagnosis of arrhythmias precipitating electrical device shock therapy. , 1991, Journal of the American College of Cardiology.

[170]  P. Tchou,et al.  Survival in Patients with Depressed Left Ventricular Function Treated by Implantable Cardioverter Defibrillator , 1991, Pacing and clinical electrophysiology : PACE.

[171]  K. Ishikawa,et al.  Effect of dipyridamole at the usual oral dose on exercise-induced myocardial ischemia in stable angina pectoris. , 1990, The American journal of cardiology.

[172]  S. Shapiro,et al.  Decline in the risk of myocardial infarction among women who stop smoking. , 1990, The New England journal of medicine.

[173]  R. Gorlin,et al.  The nature and course of depression following myocardial infarction. , 1989, Archives of internal medicine.

[174]  E. Mellits,et al.  Prophylactic antiarrhythmic therapy of high-risk survivors of myocardial infarction: lower mortality at 1 month but not at 1 year. , 1987, Circulation.

[175]  R. Byington,et al.  Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. , 1986, Circulation.

[176]  S. Shapiro,et al.  The risk of myocardial infarction after quitting smoking in men under 55 years of age. , 1985, The New England journal of medicine.

[177]  Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[178]  M. Özkaya,et al.  Action to Control Cardiovascular Risk in Diabetes , 2013 .

[179]  J. Stockman Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials , 2011 .

[180]  G. Moneta Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2010 .

[181]  T. Sakamoto,et al.  [Multicenter study for aggressive lipid-lowering strategy by HMG-CoA reductase inhibitors]. , 2009, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

[182]  Claudia Stöllberger,et al.  Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2009, Heart rhythm.

[183]  奥田 奈賀子 Relation of long chain n-3 polyunsaturated fatty acid intake to serum high density lipoprotein cholesterol among Japanese men in Japan and Japanese-American men in Hawaii : the INTERLIPID study , 2009 .

[184]  J. Marin-Neto Telmisartan, ramipril, or both in patients at high risk for vascular events , 2008 .

[185]  A. Rabinstein Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial , 2008 .

[186]  B. Gersh Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials , 2008 .

[187]  Hiroshi Takahashi,et al.  Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. , 2007, Clinical therapeutics.

[188]  S. Sasayama,et al.  Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and cheyne-stokes respiration. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[189]  M. Rich,et al.  Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. , 2006, European heart journal.

[190]  M. Hanefeld,et al.  Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. , 2004, European heart journal.

[191]  Eric J Topol,et al.  Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. , 2004, JAMA.

[192]  K. Swedberg,et al.  Expert consensus document on beta-adrenergic receptor blockers. , 2004, European heart journal.

[193]  B. Pitt,et al.  EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .

[194]  Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[195]  V. Fuster,et al.  Results of Expert Meetings: Obesity and Cardiovascular Disease. Obesity as a risk factor in coronary artery disease. , 2001, American heart journal.

[196]  Arma,et al.  EFFECTS OF MULTISITE BIVENTRICULAR PACING IN PATIENTS WITH HEART FAILURE AND INTRAVENTRICULAR CONDUCTION DELAY , 2001 .

[197]  M. C. Crim,et al.  High-intensity strength training of patients enrolled in an outpatient cardiac rehabilitation program. , 1999, Journal of cardiopulmonary rehabilitation.

[198]  R. Katori,et al.  Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. , 1997, Japanese circulation journal.

[199]  I. Nakada Prediction of exercise capacity in the chronic phase of myocardial infarction by non-supervised home exercise therapy : Consideration of physical and psychosocial factors at discharge , 1994 .

[200]  GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. , 1994, Lancet.

[201]  H. Greene Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators. , 1993, The American journal of cardiology.

[202]  M. Gheorghiade,et al.  Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. , 1993, The New England journal of medicine.

[203]  Robert Lemery,et al.  Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. , 1992, The New England journal of medicine.

[204]  Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. , 1981, The New England journal of medicine.